In a report released today, Brian Cheng from J.P. Morgan maintained a Sell rating on Allogene Therapeutics. The company’s shares closed yesterday at $1.51.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Cheng is an analyst with an average return of -11.3% and a 43.75% success rate. Cheng covers the Healthcare sector, focusing on stocks such as Roivant Sciences, Ascentage Pharma Group International Unsponsored ADR, and Allogene Therapeutics.
Allogene Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $9.40.
The company has a one-year high of $3.78 and a one-year low of $0.86. Currently, Allogene Therapeutics has an average volume of 3.88M.
Read More on ALLO:
Disclaimer & DisclosureReport an Issue
- Allogene Therapeutics’ Promising Study on LBCL Treatment with Cema-cel
- Allogene Therapeutics Earnings Call: Progress Amid Challenges
- Allogene Therapeutics management to meet with Piper Sandler
- Allogene Therapeutics Faces Financial Uncertainty Amid New U.S. Tariffs and Regulatory Challenges
- Promising Pipeline and Strategic Advancements Drive Buy Rating for Allogene Therapeutics
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
